211 Mt. Airy Road
Tel: (908) 992-6400
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
416 articles with Daiichi Sankyo
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020
HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor and platinum-based chemotherapy in first presentation of dose expansion data for patritumab deruxtecan
GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.da
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer Phase 2 study to evaluate patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, in previously treated patients with HER3 expressing advanced/metastatic colorectal cancer Initiation of third clinical study of patritumab deruxtecan demonstrates the commitment of Daiichi Sankyo to evaluate targe
AnHeart Therapeutics, Co., Ltd., a clinical stage oncology company focused on underserved patients in global markets, has through its subsidiary AnHeart Therapeutics Inc. entered into license agreements with Daiichi Sankyo Company, Limited to acquire rights to two novel clinical stage oncology candidates.
Privately-held Rain Therapeutics closed a $63 million Series B financing round that will be used to advance the company’s pipeline of targeted cancer therapies, including RAIN-32, its recently acquired asset from Daiichi Sankyo.
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), and TAGRISSO (osimertinib), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients wi
SIT Laboratorio Farmaceutico, a company of DESMA HC Group, Acquires LOPRESSOR®, ICAZ® and MIOREL® from Daiichi Sankyo France
Daiichi Sankyo France /(hereafter, Daiichi Sankyo) and SIT Laboratorio Farmaceutico (DESMA HC Group) are pleased to announce the acquisition of LOPRESSOR®, ICAZ® and MIOREL® by SIT Laboratorio Farmaceutico from Daiichi Sankyo France, effective from 30 th June 2020 .
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in phase 1 clinical development for non-small cell lung cancer and triple negative breast cancer.
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo Company for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) for multiple cancer types.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the first patient with triple negative breas
Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer
Agreement centers on identifying HER2 gene mutations using Oncomine Dx Target Test
The diagnostic tool will use Thermo Fisher’s next-generation sequencing (NGS)-based Oncomine Dx Target Test to identify HER2 (human epidermal growth factor receptor 2) gene mutations.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
Daiichi Sankyo announced on May 28 that it had entered an agreement with Syneos Health to form a coalition dedicated to bringing new cancer therapies to patients in a safe and effective manner.
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® achieved a clinically meaningful tumor response in patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer whose disease had progressed following one or more systemic therapies.
ENHERTU (fam-trastuzumab deruxtecan-nxki) Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01
Results from the ongoing Phase II DESTINY-CRC01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside the United States and Canada, to evaluate the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA® in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.
Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline
Daiichi Sankyo and Syneos Health ® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline Coalition ignites strategic insights sooner to accelerate patient access
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
ENHERTU is the second innovative oncology medicine to be launched in Japan from the oncology pipeline of Daiichi Sankyo in the past year